Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Gavreto is a RET-targeted, once-daily oral therapy developed by Blueprint Medicines. Credit: Roche.



  • Gavreto (pralsetinib)
  • Gavreto (pralsetinib)
  • Gavreto (pralsetinib)